Last reviewed · How we verify
Plasma collection
At a glance
| Generic name | Plasma collection |
|---|---|
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia
- Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies
- Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations
- The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer (PHASE1)
- Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer (PHASE3)
- The Body's Affect on Vitamin C (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma collection CI brief — competitive landscape report
- Plasma collection updates RSS · CI watch RSS
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano portfolio CI